Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: Results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction-51)

Journal of the American College of Cardiology

Volumn 61, Issue 18, 2013, Pages 1853-1859

  Mega, Jessica L ^a   Braunwald, Eugene ^a   Murphy, Sabina A ^a   Plotnikov, Alexei N ^b   Burton, Paul ^b   Kiss, Robert Gabor ^c   Parkhomenko, Alexander ^d   Tendera, Michal ^e   Widimsky, Petr ^f   Gibson, C Michael ^a,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Military Hospital   (Hungary)

^d National Institute of Cardiology   (Ukraine)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f CHARLES UNIVERSITY   (Czech Republic)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

anticoagulant; ST segment elevation myocardial infarction; therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RIVAROXABAN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; THIOPHENES; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 84876963408     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.01.066     Document Type: Article

References (8)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
2. E.G. Nabel, E. Braunwald A tale of coronary artery disease and myocardial infarction N Engl J Med 366 2012 54 63
3. K.A. Fox, F.A. Anderson Jr., S.G. Goodman Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry Nat Clin Pract Cardiovasc Med 5 2008 580 589
4. C.M. Gibson, J.L. Mega, P. Burton Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 2011 815 821 e6
5. J.L. Mega, E. Braunwald, S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
6. G. Montalescot, S.D. Wiviott, E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
7. P.G. Steg, S. James, R.A. Harrington Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
8. G. Lemesle, F. Paparoni, C. Delhaye, L. Bonello, J.M. Lablanche Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature Hosp Pract (Minneap) 39 2011 32 40